Atypical kinetic profiles in drug metabolism reactions
JM Hutzler, TS Tracy - Drug metabolism and disposition, 2002 - ASPET
The cytochrome P450 enzymes are involved in the biotransformation of both xenobiotic and
endobiotic hydrophobic compounds, implicated in the bioactivation of certain …
endobiotic hydrophobic compounds, implicated in the bioactivation of certain …
Challenges and opportunities with non-CYP enzymes aldehyde oxidase, carboxylesterase, and UDP-glucuronosyltransferase: focus on reaction phenotyping and …
UA Argikar, PM Potter, JM Hutzler, PH Marathe - The AAPS journal, 2016 - Springer
… Hutzler and colleagues expanded this research by determining AO activity using O 6 -benzylguanine
in cryopreserved human hepatocytes prepared from 75 individual donors (28). …
in cryopreserved human hepatocytes prepared from 75 individual donors (28). …
Strategies for a comprehensive understanding of metabolism by aldehyde oxidase
JM Hutzler, RS Obach, D Dalvie… - Expert opinion on drug …, 2013 - Taylor & Francis
Introduction: Aldehyde oxidase (AO) is a drug-metabolizing molybdo-flavoenzyme with
profound species differences in expression and activity toward various substrates. The …
profound species differences in expression and activity toward various substrates. The …
Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures
BJ Komoroski, S Zhang, H Cai, JM Hutzler… - Drug metabolism and …, 2004 - ASPET
St. John's wort extract (SJW) (Hypericum perforatum L.) is among the most commonly used
herbal medications in the United States. The predominance of clinical reports indicates that …
herbal medications in the United States. The predominance of clinical reports indicates that …
In vitro metabolism of clindamycin in human liver and intestinal microsomes
MA Wynalda, JM Hutzler, MD Koets, T Podoll… - Drug metabolism and …, 2003 - ASPET
Incubations with human liver and gut microsomes revealed that the antibiotic, clindamycin,
is primarily oxidized to form clindamycin sulfoxide. In this report, evidence is presented that …
is primarily oxidized to form clindamycin sulfoxide. In this report, evidence is presented that …
Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model
JM Hutzler, MJ Hauer, TS Tracy - Drug metabolism and disposition, 2001 - ASPET
… It is worthy to note that piroxicam has been shown to exhibit substrate inhibition in
microsomes and baculovirus-expressed CYP2C9 (JM Hutzler and TS Tracy, unpublished data). …
microsomes and baculovirus-expressed CYP2C9 (JM Hutzler and TS Tracy, unpublished data). …
Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator?
CD Linder, NA Renaud, JM Hutzler - Drug metabolism and disposition, 2009 - ASPET
1-Aminobenzotriazole (1-ABT) is generally considered to be a nonselective mechanism-based
inactivator of both human and non-human cytochrome P450 (P450) enzymes. Thus, 1-…
inactivator of both human and non-human cytochrome P450 (P450) enzymes. Thus, 1-…
Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes
JM Hutzler, YS Yang, D Albaugh, CL Fullenwider… - Drug Metabolism and …, 2012 - ASPET
Substrates of aldehyde oxidase (AO), for which human clinical pharmacokinetics are reported,
were selected and evaluated in pooled mixed-gender cryopreserved human hepatocytes …
were selected and evaluated in pooled mixed-gender cryopreserved human hepatocytes …
Visible spectra of type II cytochrome P450-drug complexes: evidence that “incomplete” heme coordination is common
CW Locuson, JM Hutzler, TS Tracy - Drug metabolism and disposition, 2007 - ASPET
… , JM Hutzler, and TS Tracy, unpublished data). This observation suggests that the multiple
binding phases result from a single nitrogen or that the methyl group does not sufficiently …
binding phases result from a single nitrogen or that the methyl group does not sufficiently …
Polymorphic variants (CYP2C9* 3 and CYP2C9* 5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles
TS Tracy, JM Hutzler, RL Haining, AE Rettie… - Drug Metabolism and …, 2002 - ASPET
CYP2C9 wild-type protein has been shown to exhibit atypical kinetic profiles of metabolism
that may affect in vitro-in vivo predictions made during the drug development process. …
that may affect in vitro-in vivo predictions made during the drug development process. …